BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by ...
ZME Science on MSN2d
A New Antibiotic Was Hiding in Backyard Dirt and It Might Save MillionsThey found a new molecule named lariocidin —a potential new antibiotic with the power to kill some of the world’s most ...
Pharmaceutical Technology on MSN2d
BioVersys secures patent claims in China for BV100Biopharmaceutical company BioVersys has announced the grant of key patent claims in China for BV100, the intravenous ...
Q4 2024 Earnings Call Transcript March 26, 2025 Dyadic International, Inc. misses on earnings expectations. Reported EPS is $ ...
Scientists at Oak Ridge National Laboratory have developed the first-ever method of detecting ribonucleic acid, or RNA, ...
Unlike animals, plants do not possess an adaptive immune system with antibodies or T cells to fight viral infections. Instead ...
COCP READ THE FULL COCP RESEARCH REPORT Business Update Update on CDI-988 On January 8, 2025, Cocrystal Pharma, Inc.
AIRNA’s lead candidate AIR-001 works by correcting the most common pathologic mutation driving the rare disease alpha-1 ...
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) has become the most prevalent type of heart failure, but ...
Human extracellular matrices can be edited in their composition using the CRISPR/Cas9 system, leading to materials exhibiting tailored regenerative capacities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback